Alphatec Holdings, Inc. (NASDAQ:ATEC) EVP David Sponsel Sells 33,732 Shares

Alphatec Holdings, Inc. (NASDAQ:ATEC) EVP David Sponsel sold 33,732 shares of the stock in a transaction that occurred on Thursday, March 6th. The stock was sold at an average price of $10.83, for a total transaction of $365,317.56. Following the completion of the sale, the executive vice president now directly owns 668,977 shares of the company’s stock, valued at $7,245,020.91. This trade represents a 4.80 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

David Sponsel also recently made the following trade(s):

• On Monday, February 24th, David Sponsel sold 12,946 shares of Alphatec stock. The shares were sold at an average price of $10.73, for a total transaction of $138,910.58.
• On Monday, February 3rd, David Sponsel sold 36,256 shares of Alphatec stock. The shares were sold at an average price of $11.42, for a total transaction of $414,043.52.
• On Monday, January 13th, David Sponsel sold 58,283 shares of Alphatec stock. The shares were sold at an average price of $10.71, for a total transaction of $624,210.93.
• On Friday, January 10th, David Sponsel sold 238 shares of Alphatec stock. The shares were sold at an average price of $10.00, for a total value of $2,380.00.

Alphatec Trading Down 7.6 %

ATEC stock traded down $0.79 during mid-day trading on Monday, reaching $9.67. The company’s stock had a trading volume of 3,116,344 shares, compared to its average volume of 1,980,921. The company has a current ratio of 2.32, a quick ratio of 1.15 and a debt-to-equity ratio of 30.21. Alphatec Holdings, Inc. has a 12 month low of $4.88 and a 12 month high of $14.88. The business’s 50 day moving average price is $10.91 and its 200 day moving average price is $8.64. The company has a market cap of $1.39 billion, a price-to-earnings ratio of -7.55 and a beta of 1.39.

Alphatec (NASDAQ:ATEC) last announced its earnings results on Wednesday, February 26th. The medical technology company reported ($0.23) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by ($0.04). The company had revenue of $176.79 million for the quarter, compared to analysts’ expectations of $172.74 million. Alphatec had a negative net margin of 31.06% and a negative return on equity of 541.39%. On average, equities research analysts predict that Alphatec Holdings, Inc. will post -1.08 EPS for the current year.

Analysts Set New Price Targets

ATEC has been the topic of several research reports. Barclays upped their price objective on Alphatec from $20.00 to $21.00 and gave the stock an “overweight” rating in a report on Wednesday, January 22nd. StockNews.com upgraded shares of Alphatec from a “sell” rating to a “hold” rating in a research report on Friday, February 28th. Piper Sandler lifted their price target on shares of Alphatec from $12.00 to $13.00 and gave the company an “overweight” rating in a research note on Thursday, February 27th. Needham & Company LLC reiterated a “buy” rating and set a $16.00 price objective on shares of Alphatec in a report on Thursday, February 27th. Finally, HC Wainwright reiterated a “buy” rating and issued a $20.00 price target on shares of Alphatec in a research note on Tuesday, January 14th. Two research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $17.67.

Institutional Trading of Alphatec

Hedge funds and other institutional investors have recently modified their holdings of the business. Creative Planning boosted its position in shares of Alphatec by 83.9% in the third quarter. Creative Planning now owns 48,611 shares of the medical technology company’s stock valued at $270,000 after acquiring an additional 22,171 shares during the period. Van ECK Associates Corp increased its holdings in shares of Alphatec by 57.0% in the third quarter. Van ECK Associates Corp now owns 19,273 shares of the medical technology company’s stock worth $99,000 after buying an additional 6,998 shares during the period. Atria Investments Inc boosted its position in Alphatec by 8.0% during the 3rd quarter. Atria Investments Inc now owns 19,609 shares of the medical technology company’s stock valued at $109,000 after buying an additional 1,460 shares during the period. Entropy Technologies LP grew its holdings in Alphatec by 14.9% in the 3rd quarter. Entropy Technologies LP now owns 21,623 shares of the medical technology company’s stock worth $120,000 after acquiring an additional 2,800 shares during the last quarter. Finally, GSA Capital Partners LLP purchased a new position in shares of Alphatec in the third quarter valued at about $431,000. Institutional investors own 66.35% of the company’s stock.

About Alphatec

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.